Stock SUPRIYA SUPRIYA LIFESCIENCE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Supriya Lifescience Limited

Equities

SUPRIYA

INE07RO01027

Pharmaceuticals

End-of-day quote NSE India S.E.
Other stock markets
 03:30:00 15/05/2024 am IST 		5-day change 1st Jan Change
378.8 INR -1.03% Intraday chart for Supriya Lifescience Limited -1.42% +20.37%
07/02 Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
07/02 Supriya Lifescience Limited Announces Approval of Capital Expenditure at Ambernath Site for CDMO Facility CI

Valuation

Fiscal Period: March 2022 2023 2024 2025 2026
Capitalization 1 39,702 15,352 30,394 - -
Enterprise Value (EV) 1 39,702 15,352 30,394 30,394 30,394
P/E ratio 26.2 x 17.1 x 26.5 x 20.4 x 16.5 x
Yield - - - - -
Capitalization / Revenue - 3.33 x 5.41 x 4.43 x 3.63 x
EV / Revenue - 3.33 x 5.41 x 4.43 x 3.63 x
EV / EBITDA - 11.9 x 18.7 x 15.3 x 12.5 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 80,483 80,483 80,483 - -
Reference price 2 493.3 190.8 378.8 378.8 378.8
Announcement Date 20/05/22 26/05/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2022 2023 2024 2025 2026
Net sales 1 - 4,609 5,617 6,864 8,376
EBITDA 1 - 1,289 1,628 1,991 2,429
EBIT 1 - - 1,469 1,865 2,276
Operating Margin - - 26.15% 27.17% 27.17%
Earnings before Tax (EBT) 1 - 1,235 1,565 1,948 2,357
Net income 1 1,518 898.6 1,148 1,500 1,846
Net margin - 19.49% 20.44% 21.85% 22.04%
EPS 2 18.86 11.16 14.30 18.60 22.90
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 20/05/22 26/05/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 1,014 1,122 - 1,423 1,320 1,345 1,211 1,495
EBITDA 1 312.4 515.4 - 550.4 444.9 400 341 453
EBIT - - - - - - - -
Operating Margin - - - - - - - -
Earnings before Tax (EBT) - - - - - - - -
Net income - - 95.18 - - - - -
Net margin - - - - - - - -
EPS - - 1.180 - - - - -
Dividend per Share - - - - - - - -
Announcement Date 12/08/22 10/11/22 14/02/23 26/05/23 03/08/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 13.7% 14.2% 15.7% 16.3%
ROA (Net income/ Total Assets) - 11.6% 12.1% 13.5% 14%
Assets 1 - 7,775 9,488 11,111 13,186
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 20/05/22 26/05/23 - - -
1INR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Supriya Lifescience Limited

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SUPRIYA LIFESCIENCE LIMITED Stock Supriya Lifescience Limited
+20.37% 365M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.81% 709B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.06% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.07% 367B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.64% 334B
ABBVIE INC. Stock AbbVie Inc.
+5.14% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.43% 239B
NOVARTIS AG Stock Novartis AG
+9.20% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-3.48% 203B
AMGEN INC. Stock Amgen Inc.
+8.59% 171B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SUPRIYA Stock
  4. Financials Supriya Lifescience Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW